News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • A 10-day ceasefire largely holds between Lebanon and Israel, allowing some displaced Lebanese to begin cautious returns amid reported destruction.
  • U.S. futures were subdued as markets weighed potential U.S.-Iran talks and a confirmation hearing for Fed nominee Kevin Warsh.
  • Brent crude slipped below $100 a barrel on ceasefire hopes, easing near-term energy-driven inflation pressure.
  • Netflix stock dropped after a softer revenue outlook and news chairman Reed Hastings will not seek re-election.
  • Bouygues, Iliad and Orange entered exclusive talks to buy SFR for €20.35 billion, proposing shared infrastructure and split consumer operations.
  • OnlyFans is nearing sale of a minority stake to Architect Capital at a valuation above $3 billion, targeting creator financial services.

Latest Articles

VivoSim Announces Pricing of up to a $4 Million Public Offering

VivoSim Announces Pricing of up to a $4 Million Public Offering

VivoSim Labs, a Nasdaq-listed biotech company specializing in next-generation New Approach Methodologies (NAMs) for preclinical safety testing using 3D human tissue models, has announced the pricing of a $4 million public offering. The offering comprises an initial $3 million closing and an additional $1 million tranche contingent on conditions suc…

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Ardelyx, a US-based biopharmaceutical company, announced the appointment of Dr. Rajani Dinavahi as its new Chief Medical Officer. With over 20 years of experience in biotechnology and healthcare, Dr. Dinavahi will lead clinical development and medical affairs to strengthen Ardelyx's pipeline and advance its innovative medicines to market. This lead…

NOVAGOLD Files First Quarter 2026 Report Highlighting Growing Momentum on Key Donlin Gold Workstreams

NOVAGOLD Files First Quarter 2026 Report Highlighting Growing Momentum on Key Donlin Gold Workstreams

NOVAGOLD Resources Inc. reported significant progress in the first quarter of 2026 on its Donlin Gold project, highlighted by the launch of a Bankable Feasibility Study (BFS) led by Fluor Corporation and awarding strategic engineering contracts to advance critical infrastructure. The company completed an upsized private placement raising approximat…

Apollo Funds Acquire Gatehouse Living Group from Gatehouse Bank

Apollo Funds Acquire Gatehouse Living Group from Gatehouse Bank

Apollo Global Management announced that funds it manages have acquired Gatehouse Living Group (GLG), a leading UK residential investment and property management platform, from Gatehouse Bank. The acquisition enhances Apollo's presence in the UK housing market, complementing its existing investments in UK homebuilding and mortgage lending. GLG will …

Tri Pointe Homes Named to 2026 Fortune 100 Best Companies to Work For® List, Honoring its Dedication to People-First Culture, Innovation, and Career Growth

Tri Pointe Homes Named to 2026 Fortune 100 Best Companies to Work For® List, Honoring its Dedication to People-First Culture, Innovation, and Career Growth

Tri Pointe Homes (NYSE: TPH), a major U.S. homebuilder, has been named to the 2026 Fortune 100 Best Companies to Work For list for the third time, recognizing its commitment to a people-first culture, innovation, and career growth. The company continues to enhance professional development, implement AI and technology initiatives, expand recruiting …

Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

Calidi Biotherapeutics will present new data on its RedTail virotherapy platform at the AACR Annual Meeting 2026, highlighting its novel approach to simultaneously activate T-cells and induce high expression of T-cell engagers specifically in the tumor microenvironment. The company’s lead candidate, CLD-401, targets multiple solid tumors and is pro…

Nanox Signs Distribution Agreement with Elite Surgical Technologies to Deploy Nanox.ARC in Key U.S. Markets

Nanox Signs Distribution Agreement with Elite Surgical Technologies to Deploy Nanox.ARC in Key U.S. Markets

Nano-X Imaging Ltd. (NASDAQ: NNOX) announced a distribution agreement with Elite Surgical Technologies to deploy the Nanox.ARC digital tomosynthesis imaging system across five U.S. states, targeting orthopedic practices and post-surgical care settings. The partnership aims to enhance adoption of cost-effective, low-radiation 3D imaging to monitor b…

WTW completes acquisition of FlowStone Partners

WTW completes acquisition of FlowStone Partners

Willis Towers Watson (WTW) has completed the acquisition of FlowStone Partners, an alternative investment firm specializing in private equity secondaries. This move enhances WTW's Investments business by expanding access to private equity solutions for individual wealth investors and bringing advanced investment capabilities to institutional client…

Greenlane Holdings, Inc. Announces 1-for-8 Reverse Stock Split

Greenlane Holdings, Inc. Announces 1-for-8 Reverse Stock Split

Greenlane Holdings, Inc., a Nasdaq-listed digital asset treasury company focused on Berachain blockchain assets, announced a 1-for-8 reverse stock split effective April 6, 2026. The split aims to improve the perception of its stock, broaden investor appeal, and maintain compliance with Nasdaq listing rules. The total shares outstanding will reduce …

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

Cogent Biosciences has completed the submission of a New Drug Application (NDA) to the FDA for bezuclastinib in treatment-resistant Gastrointestinal Stromal Tumors (GIST) patients, based on strong Phase 3 PEAK trial results. The application was submitted under the FDA's expedited Real-Time Oncology Review program. The PEAK trial demonstrated signif…